Publications
November 12, 2021
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (video)
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (video)
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
Novel DNAM-1 Axis Member, PVRIG, is Potentially a Dominant Checkpoint Involved in Stem-Like Memory T Cell – Dendritic Cell Interaction
Zoya Alteber, et al, SITC 2021 annual meeting
Novel DNAM-1 Axis Member, PVRIG, is Potentially a Dominant Checkpoint Involved in Stem-Like Memory T Cell – Dendritic Cell Interaction (video)
Zoya Alteber, et al, SITC 2021 annual meeting
June 29, 2021
The TIGIT Pathway, PVRIG, a Novel Pathway Member, Targets for Cancer Immunotherapy: A Deep Dive
Eran Ophir, VP Research and Drug Discover June 2021.
June 8, 2021
COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716)
Daniel A. Vaena, et al, ASCO Annual Meeting
April 13, 2021
Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis
Zoya Alteber, Maya F Kotturi, Sarah Whelan, et al.
November 5, 2020
PVRIG is a novel NK cell immune checkpoint receptor in acute myeloid leukemia
Jessica Li, et al, Haematologica
